Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia

Internal Medicine

Volumn 55, Issue 8, 2016, Pages 969-973

  Tada, Kazuhiro ^a   Ito, Kenji ^a   Hamauchi, Aki ^a   Takahashi, Koji ^a   Watanabe, Renya ^a   Uchida, Ai ^a   Abe, Yasuhiro ^a   Yasuno, Tetsuhiko ^a   Miyake, Katsuhisa ^a   Sasatomi, Yoshie ^a   Nakashima, Hitoshi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Alternative pathway; Atypical hemolytic uremic syndrome; Clopidogrel; Plasma exchange; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

CLOPIDOGREL; COMPLEMENT COMPONENT C3; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; TICLOPIDINE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BLOOD LEVEL; BRAIN INFARCTION; CAPSULA INTERNA; CASE REPORT; CHOLURIA; COMPLEMENT HEMOLYSIS TEST; CONJUNCTIVA DISEASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EDEMA; FATIGUE; HEMATURIA; HEMODIALYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; HYPOCOMPLEMENTEMIA; LATENT PERIOD; LOSS OF APPETITE; MALE; NAUSEA; OLIGURIA; PATHOLOGY; PLASMAPHERESIS; PROTEINURIA; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANEMIA, HEMOLYTIC; CEREBRAL INFARCTION; CHEMICALLY INDUCED; COMPLICATION; PLASMA EXCHANGE; THROMBOTIC MICROANGIOPATHIES;

ACUTE KIDNEY INJURY; ADRENAL CORTEX HORMONES; AGED; ANEMIA, HEMOLYTIC; CEREBRAL INFARCTION; HUMANS; MALE; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; THROMBOTIC MICROANGIOPATHIES; TICLOPIDINE;

EID: 84963516592     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5703     Document Type: Article

References (26)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 24: 21-24, 1924.
2. Moake JL. Thrombotic microangiopathies. N Engl J Med 347: 589-600, 2002.
3. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpula, and other thrombotic microangiopathies and coagulopathies. In: Heptinstall’s Pathology of the Kidney. 6th ed. Jennett J, et al, Eds. Lippincott Williams & Wilkins, Philadelphia, 2007: 699-762.
4. Javett SN, Senior B. Syndrome of hemolysis, thrombopenia and nephropathy in infancy. Pediatrics 29: 209-223, 1962.
5. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drugrelated serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol 77: 316-318, 2004.
6. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrelassociated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35: 533-537, 2004.
7. Bennett CL, Kiss JE, Weinberg PD, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 352: 1036-1037, 1998.
8. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281: 806-810, 1999.
9. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ti clopidine after intracoronary stent placement. J Am Coll Cardiol 34: 1891-1894, 1999.
10. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 82: E266-E355, 2013.
11. Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 38: 845-853, 2012.
12. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342: 1773-1777, 2000.
13. Pharmaceuticals and Medical Devices Agency [Internet]. [cited 2014 Jan. 30]. Available from: http://www.info.pmda.go.jp/fsearch new/jsp/menu_fukusayou_base.jsp
14. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 50: 1138-1143, 2007.
15. Furlan M, Robles R, Galbusera M, et al. von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584, 1998.
16. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103: 4043-4049, 2004.
17. Reis ES, Falcao DA, Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 63: 155-168, 2006.
18. Ghannam A, Pernollet M, Fauquert JL, et al. Human C3 deficiency associated with impairments in dendritic cell differentiation, memory B cells, and regulatory T cells. J Immunol 181: 5158-5166, 2008.
19. Matsuyama W, Nakagawa M, Takashima H, Muranaga F, Sano Y, Osame M. Identification of a novel mutation (Tyr1081Ter) in sisters with hereditary component C3 deficiency and SLE-like symptoms. Hum Mutat 17: 79, 2001.
20. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009.
21. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138: 412-417, 2001.
22. Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/ CFHR3 deficiency. Blood 111: 1512-1514, 2008.
23. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554-562, 2013.
24. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859, 2010.
25. Chapin J, Eyler S, Smith R, Tsai HM, Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood 121: 4012-4013, 2013.
26. Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66: 857-868, 2015.